PropertyValue
?:abstract
  • Infection of lung cells by the corona virus results in a loss of the balance between, on the one hand, angiotensin II-mediated stimulation of the angiotensin II type 1 receptor and, on the other hand, stimulation of the angiotensin II type 2 receptor and/or the Mas receptor. The unbalanced enhanced stimulation of the angiotensin II type 1 receptor causes inflammation, edema and contributes to the pathogenesis of severe acute respiratory distress syndrome. Here we hypothesize that stable, receptor-specific agonists of the angiotensin II type 2 receptor and of the Mas receptor are molecular medicines to treat COVID-19 patients. These agonists have therapeutic potential in the acute disease but in addition may reduce COVID-19-associated long-term pulmonary dysfunction and overall end-organ damage of this disease.
?:creator
?:doi
  • 10.1186/s10020-020-00211-0
?:doi
?:journal
  • Mol_Med
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/2ecda4f1df5c5d08ae3f908b588426cb40b281af.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7430134.xml.json
?:pmcid
?:pmid
?:pmid
  • 32807075.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19?
?:type
?:year
  • 2020-08-17

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/iccaqz8u>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/iccaqz8u>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all